MGMT and glioblastoma: We subsequently investigated two human equivalent TMZ doses in vivo, and demonstrated that 164 mg/m2 was more effective than 84 mg/m2 as it led to (i) rapid and sustained tumour shrinkage, and (ii) prolonged progression free and overall survival in animals bearing patient-derived GBM with unmethylated MGMT promoter.